Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 14/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27395308 | 1.00 | HDAC4 (0.41) | HDAC4HDAC6CNR2CYP1A2CYP2D6 | |
| SCHEMBL27213729 | 0.86 | HDAC4 (0.46) | HDAC4HDAC6CNR2CYP2C9MCHR1 | |
| SCHEMBL27230956 | 0.86 | HDAC4 (0.46) | HDAC4HDAC6CNR2CYP2C9MCHR1 | |
| SCHEMBL27394716 | 0.86 | CNR2 (0.41) | HDAC4HDAC6CNR2CYP1A2CYP2D6 | |
| SCHEMBL29318609 | 0.86 | CNR2 (0.41) | HDAC4HDAC6CNR2CYP1A2CYP2D6 | |
| SCHEMBL30892989 | 0.86 | CNR2 (0.41) | HDAC4HDAC6CNR2CYP1A2CYP2D6 | |
| SCHEMBL27395307 | 0.86 | HDAC4 (0.47) | HDAC4HDAC6CNR2CYP1A2CYP2D6 | |
| SCHEMBL30892966 | 0.86 | HDAC4 (0.47) | HDAC4HDAC6CNR2CYP1A2CYP2D6 | |
| SCHEMBL27213902 | 0.82 | HDAC4 (0.44) | HDAC4HDAC6CNR2MCHR1HTR1A | |
| SCHEMBL27231174 | 0.82 | HDAC4 (0.44) | HDAC4HDAC6CNR2MCHR1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | HDAC4 450/4885HDAC6 888/4885CNR2 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.